Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BPN 14770

Drug Profile

BPN 14770

Alternative Names: BPN-14770

Latest Information Update: 04 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tetra Discovery Partners
  • Developer Rush University Medical Center; Tetra Therapeutics
  • Class Acetamides; Amines; Antidementias; Benzeneacetamides; Chlorobenzenes; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase II Alzheimer's disease; Fragile X syndrome

Most Recent Events

  • 02 Nov 2020 Efficacy and adverse events data from a phase II trial in Fragile X syndrome released by Tetra Therapeutics
  • 02 Nov 2020 Tetra Discovery Partners completes enrolment in a phase II trial for Fragile X syndrome in USA (PO), prior to November 2020 (NCT03569631)
  • 26 May 2020 Tetra Discovery Partners completes a phase-II Tetra PICASSO AD clinical trials in Alzheimer's disease (In adults, In the elderly, Early-stage disease) in USA (PO) (NCT03817684)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top